Medroxyprogesterone acetate
As of the edition of 20 October 2026, Medroxyprogesterone acetate is a small molecule: marketed, first approved in 1964 (CH); acts on PGR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Depo-Provera
- First approved
- 3 June 1964 (CH)
- Approvals on record
- 22 in 6 regions
- Holder of the most recent approval
- Pfizer; 4 holders in all
- Registered trials
- 98, 10 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Cancer; Immune system; Infections; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Medroxyprogesterone acetate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PGR | Progesterone receptor | P06401 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 26 | 20 | 4 | 2 |
| Phase 1 | 12 | 9 | 0 | 3 |
| Phase 2 | 14 | 8 | 1 | 2 |
| Phase 3 | 27 | 20 | 4 | 2 |
| Phase 4 | 19 | 11 | 3 | 1 |
| All trials | 98 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1964 to now |
| Kyowa Kirin | Applicant |